Raleigh’s Aceragen, Arrevus Combine Forces to Tackle Rare Diseases

Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus.

Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline

Combination advances strategy of building multi-product commercial rare disease company Portfolio to address Farber disease, Cystic Fibrosis, and Orphan Infectious Diseases RALEIGH-DURHAM, NC – October 28, 2021 – Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and orphan diseases, today announced the acquisition of Arrevus, Inc., a clinical-stage biopharmaceutical company developing